Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has received a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $13.70.

Several equities research analysts recently issued reports on VNDA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Friday, July 17th. B. Riley Financial reaffirmed a “buy” rating and set a $12.00 target price (down from $17.00) on shares of Vanda Pharmaceuticals in a research report on Monday, August 10th. Finally, HC Wainwright reduced their target price on Vanda Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, August 10th.

Institutional Trading of Vanda Pharmaceuticals

A number of large investors have recently modified their holdings of VNDA. Monaco Asset Management SAM bought a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter worth approximately $1,354,000. BlackRock Inc. purchased a new position in shares of Vanda Pharmaceuticals in the second quarter valued at about $46,841,000. Arrowstreet Capital Limited Partnership bought a new position in shares of Vanda Pharmaceuticals during the first quarter valued at about $1,668,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Vanda Pharmaceuticals during the second quarter valued at about $1,317,000. Finally, AIGH Capital Management LLC purchased a new position in Vanda Pharmaceuticals during the 2nd quarter valued at $12,510,000. Institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Price Performance

Shares of VNDA stock opened at $5.09 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.60 and a current ratio of 1.61. The stock has a market capitalization of $307.74 million, a PE ratio of -1.10 and a beta of 0.64. The stock’s fifty day moving average is $5.42 and its 200-day moving average is $6.41. Vanda Pharmaceuticals has a 52 week low of $4.27 and a 52 week high of $9.94.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.46). Vanda Pharmaceuticals had a negative return on equity of 49.81% and a negative net margin of 127.41%.The company had revenue of $50.53 million for the quarter, compared to analyst estimates of $61.92 million. Equities research analysts expect that Vanda Pharmaceuticals will post -3 EPS for the current fiscal year.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.